- Eva Kučerová, MDHead of Regulatory Affairs, Qualified Person
- Mgr. Eva AdamusováHead of Regulatory Affairs
- Serhiy Forostyak, MD, Ph.D.Chief Scientific Officer
- Petr Koška, M.Eng., MBAChief Executive Officer
- Mgr. Iveta SchmiedováHead of Amnio based products
- Václav Jirků, MDMember of the Board of Trustees
- Mgr. Igor HlásenskýHead of Legal Department
- Jiří Matuška, MDMember
- Ivo Kristen, M. Eng.Member of the Board of Trustees
- Elen Šťastná, MDHead of Public Affairs
- Zdeněk Kořístek, MDMember
- Michal Zahradníček, M. Eng., MBAChairman of the Board of Trustees
- Petr Čumba, M.Eng.Chief financial officer
- Ing. Jan Lipenský, Ph.D.Principal Investigator Biotechnology Research Program
Eva Kučerová, MD
Head of Regulatory Affairs, Qualified PersonEva Kučerová received her degree at the Masaryk University Brno in microbiology and molecular biology. As of 2005, she has been involved in the area of research within the field of mesenchymal stem cells and cell cultivations. In the meantime, she has also participated in a variety of clinical studies and for a period of five years she has been working as a research fellow in treatments of leukaemia at the Faculty of Medicine at the Masaryk University Brno. In 2008 she was named the Head of the Cell Therapy Department at Tissue Bank at the University Hospital Brno. Since 2009 she has worked as Qualified Person and in the same year she has been appointed Head of the Department of Cell Transplants at the National Cell and Tissue Centre. She is also responsible for clinical trials.
Actively participating at national and international conferences, presenting new research findings, Eva Matějková is a renowned professional within the field of Advanced Therapies.
Mgr. Eva Adamusová
Head of Regulatory AffairsEva Adamusova graduated from the Faculty of Science at Charles University for Biochemistry in 2008. After graduation she continued the work from her diploma thesis at the Department of Cellular Neurophysiology at Physiological Institute at Czech Academy of Sciences. Her research focused on an influence of neurostereoids on NMDA receptors using transfected HEK cells and primary cultures from hippocampal neurons.
Since 2013 Eva has been working in the area of medical devices. During her career she worked for a manufacturer, distributors and also a Notified Body for medical devices.
As a Project Manager in Medicem Institute, she coordinated activities during preclinical phase of medical device development and planned clinical evaluations, product launches and post-market surveillance plans. Eva also has experience working with the Electrotechnical Testing Institute where she participated in technical file/design dossier assessments. Following this, Eva worked for several large device corporations such as Johnson & Johnson and Philips Healthcare. During this time, Eva was responsible for registration of medical devices in eighteen (18) central and eastern Europe countries where she also developed and implemented a vigilance process that standardized and reduce reporting requirements and timelines.
In her most recent role prior to joining Primecell Eva was a subject matter expert leading EU MDR implementation for international markets.
Serhiy Forostyak, MD, Ph.D.
Chief Scientific OfficerDr. Forostyak has graduated from a Faculty of Medicine at Ternopil’ State Medical University, Ukraine in 2005 (with honours). After receiving his first degree specialization in the field of general surgery (2008) Dr. Forostyak has continued his education at the 2nd Faculty of Medicine at Charles University in Prague and Institute of Experimental Medicine at Czech Academy of Sciences.
He has defended his doctoral thesis in 2012 and received a title PhD in Neuroscience. During his doctoral and postdoctoral years he has received several prestigious fellowships and awards (CORTEX: Marie Curie Early Stage Training Net; FENS Young Investigator Training Program; Czech Neuroscience Society award for best publication published by a Young Neuroscientist; Development of Research Teams for the BIOCEV; EUROCELLNET travel fellowship etc.) and underwent internship in prestigious universities (Cambridge University, UK; Katholieke Universiteit Leuven, Belgium; Neuroscience Institute Cavalieri Ottolenghi, Italy; University of Pittsburgh, USA). Dr. Forostyak’s research lays in the field of regenerative and translational medicine with a main focus on evaluation of regenerative potential of stem cells (mesenchymal stromal cells; embryonic stem cells; induced pluripotent stem cells etc.) and biomaterials, and their application to cure neurotrauma and neurodegenerative disorders. Current scientific record includes 22 publications (WOS) in prestigious international peer-reviewed journals, 3 book chapters and 3 papers are currently in press. Dr. Forostyak has been principal/co-principle investigator in several research projects. He is acting as a scientific evaluator of national and international grant agencies, but also contributes as a reviewer in prestigious scientific journals. He has been actively participating at numerous national and international conferences, but also acted as an organising committee member at several international meetings.
Petr Koška, M.Eng., MBA
Chief Executive OfficerPetr Koška is Chief Executive Officer of PrimeCell Therapeutics Inc. and Vice-Chairman of the Board of Directors of the National Cell and Tissue Centre Inc. (one of the subsidiaries of PrimeCell Therapeutics). He joined PrimeCell Therapeutics in January 2013 holding a variety of leadership positions over the course of his career. Mr Koska is a well-known professional within the healthcare industry in the Czech Republic. He is a respected manager, who boasts of many years of experience leading large medical facilities.
Prior to his position in PrimeCell Therapeutics, since 2008 he was Chief Executive Officer at one of the largest university hospitals in the Czech Republic, namely, St. Anne´s University hospital Brno. In his previous position he gained knowledge of transferring medical science and research into clinical practice. Additionally, he was the head of a unique team of professionals who were involved with the development of an international centre of clinical research within the premises of St. Anne´s hospital, namely, International Clinical Research Center (ICRC). This centre was developed in co-operation with Mayo Clinic, Rochester, Minnesota, USA.
He started his professional career in 1996 at the University hospital Brno, where he held various leading positions until 2007, when he was elected General Director. In 1997 – 1998 he was one of the three key figures involved in the most unique plan in the healthcare industry in the Czech Republic up-to-date, which was the merger of university hospitals in the Brno region.
Mr Koška graduated at the Technical University Brno. Later, he obtained the MBA degree at Prague International Business School. Currently he is the candidate for PhD in business (DBA). In 2008 – 2012 he was a member of the scientific committee at the Medical faculty of Masaryk University in Brno.
Mgr. Iveta Schmiedová
Head of Amnio based productsIveta Schmiedová has graduated in 2015 from the Faculty of Science at Masaryk University in Biochemistry.
During her studies, she worked as an intern at the University of Veterinary and Pharmaceutical Sciences in Brno where she participated in research focused on hypoglycemic prevention for her Bachelor thesis and later also Master thesis. The main focus was on the formulation and testing of micro-pharmaceutical products with high glucose content and semipermeable membrane which provided a gradual release of glucose. With this research, she won “Science Slam”, a competition which popularizes current research and development. Afterward she took part in the competition European final in Vienna.
After graduation, she worked as an analyst in company Oncomed Manufacturing, which produces cytostatic injections.
Since 2017 Iveta works at Primecell as the responsible person for amniotics membranes. She cooperated on development of AMNIODERM and is an inventor in patent CZ307603 ZPŮSOB PŘÍPRAVY MATERIÁLU NA BÁZI AMNIOVÉ MEMBRÁNY A MATERIÁL PŘIPRAVITELNÝ TÍMTO ZPŮSOBEM and patent EP3505196 METHOD OF PREPARATION OF AMNIOTIC MEMBRANE-BASED MATERIAL AND A MATERIAL OBTAINABLE BY SAID METHOD.
Václav Jirků, MD
Member of the Board of Trustees Mgr. Igor Hlásenský
Head of Legal DepartmentLegal matters of PrimeCell Therapeutics are in hands of a team of in-house lawyers led by Igor Hlásenský, young but well-experienced specialist in medical law as well as commercial and administrative law. Upon finishing his studies at the Faculty of Law of Masaryk University in Brno in 2010 he worked for a respected law firm and later moved up to the Ministry of Health to became a main lawyer, inspector, and deputy head of Inspectorate of narcotic drugs and psychotropic substances.
During his career Igor attended many conferences, trained people in legal consciousness and was a part of the European Commission delegation to Serbia for the purpose of bringing this country’s legislation into line with the European law. Igor is a major author of the text of the Czech Act On Drug Precursors and certain other general binding regulations and contributed significantly to terminate complicated and hyped cases.
Nowadays Igor is ranked among leading experts in legal obligations related to handling with tissues and cells and he strongly helps PrimeCell Therapeutics to conclude all the necessary contracts and conduct its activities in full compliance with the law.
Jiří Matuška, MD
Member Ivo Kristen, M. Eng.
Member of the Board of Trustees Elen Šťastná, MD
Head of Public AffairsDr. Elen Šťastná graduated from Charles University in Hradec Kralové in general medicine. After obtaining a first degree specialization in the field of general medicine she worked in this field until 2000. She has been involved in the projects of preventive medicine and projects aimed at improving the quality of life. She has worked at the Danish pharmaceutical and nutraceutical company Pharma Nord at managerial position in the field of education. Dr. Šťastná also provides consulting and advisory services in marketing communications activities, strategic planning and PR. She is The President of Soroptimist International Prague-world, prestigious women’s organizations with direct access to the UN and other international organizations, such as UNESCO and the Council of Europe. Soroptimist International seeks to improve access to health care, doctors, midwives and applies to the fight against the spread of AIDS and transmission of the disease from mother to newborn and improvement of living conditions of women and children.
Dr. Štastná is the founder of the AA Homolka Club at the Department of Pediatric Allergy and Clinical Immunology Hospital Homolka, whose activities contribute to the improvement of awareness and better care for children with allergy and asthma.
Zdeněk Kořístek, MD
MemberMichal Zahradníček, one of the founders of PrimeCell Therapeutics, is an investor and acts as a key figure in several high-tech companies in the Czech Republic and the Central and Eastern European region. He began his career in 1993, working as an economist for several international companies. Since 2001, he has been involved in investments in areas with high innovation potential. He acted as an advisor of the Ministry of Finance of the Slovak Republic, also taking part in health reform preparations. In 2004, he was awarded the title Manager of the Year for a Medium-Size Company and he was listed among the TOP 10 most successful Czech managers. Michal Zahradníček graduated from the Brno University of Technology. He then continued his studies at the Technical University in Darmstadt in Germany and at the Manchester Metropolitan University in the UK.
Petr Čumba, M.Eng.
Chief financial officerIng. Petr Čumba graduated in the Brno University of Technology and in the course of his career, he held management positions in financial institutions, trading and manufacturing companies. Coming from a group SAB Finance – MPU, where was working as a chief financial officer in 2013-2016, he stood at the preparation of the transformation of MPU to a bank and ensure the implementation of new European legislation for the financial sector to internal processes. During his work for both companies there has been negligible growth in their profitability.
In 2010-2012 he was responsible for the financial management of manufacturing companies BONATRANS GROUP and MANEX Industrial Automation, where he led the crisis management team that has successfully completed the reorganization of the company.
Until 2009, he worked nearly 15 years in companies operating in oil and gas division of the KKCG Group. The longest in the MND, the biggest Czech oil and gas producer, where in addition to membership in the company boards, he managed finances in the parent company and subsidiaries. He was responsible for all standard economic activities, cash flow management in the group, both internal and external financing, management of domestic and foreign subsidiaries, development of gas trading after the end of state regulation, sales of crude oil, implementation of system of central purchasing, several transformations of companies in the group and other related activities.
Ing. Jan Lipenský, Ph.D.
Principal Investigator Biotechnology Research ProgramVystudoval obor Živočišné biotechnologie na Agronomické fakultě Mendelovy univerzity v Brně. Doktorské studium absolvoval na ústavu Morfologie, fyziologie a genetiky zvířat téže fakulty. Po řadu let pracoval ve Výzkumném ústavu živočišné výroby, v.v.i. Mezi jeho zaměření patřila především oblast reprodukce a vývoje nových technologií chovu.
Eva Kučerová, MD
Eva Kučerová received her degree at the Masaryk University Brno in microbiology and molecular biology. As of 2005, she has been involved in the area of research within the field of mesenchymal stem cells and cell cultivations. In the meantime, she has also participated in a variety of clinical studies and for a period of five years she has been working as a research fellow in treatments of leukaemia at the Faculty of Medicine at the Masaryk University Brno. In 2008 she was named the Head of the Cell Therapy Department at Tissue Bank at the University Hospital Brno. Since 2009 she has worked as Qualified Person and in the same year she has been appointed Head of the Department of Cell Transplants at the National Cell and Tissue Centre. She is also responsible for clinical trials.
Actively participating at national and international conferences, presenting new research findings, Eva Matějková is a renowned professional within the field of Advanced Therapies.
Mgr. Eva Adamusová
Eva Adamusova graduated from the Faculty of Science at Charles University for Biochemistry in 2008. After graduation she continued the work from her diploma thesis at the Department of Cellular Neurophysiology at Physiological Institute at Czech Academy of Sciences. Her research focused on an influence of neurostereoids on NMDA receptors using transfected HEK cells and primary cultures from hippocampal neurons.
Since 2013 Eva has been working in the area of medical devices. During her career she worked for a manufacturer, distributors and also a Notified Body for medical devices.
As a Project Manager in Medicem Institute, she coordinated activities during preclinical phase of medical device development and planned clinical evaluations, product launches and post-market surveillance plans. Eva also has experience working with the Electrotechnical Testing Institute where she participated in technical file/design dossier assessments. Following this, Eva worked for several large device corporations such as Johnson & Johnson and Philips Healthcare. During this time, Eva was responsible for registration of medical devices in eighteen (18) central and eastern Europe countries where she also developed and implemented a vigilance process that standardized and reduce reporting requirements and timelines.
In her most recent role prior to joining Primecell Eva was a subject matter expert leading EU MDR implementation for international markets.
Serhiy Forostyak, MD, Ph.D.
Dr. Forostyak has graduated from a Faculty of Medicine at Ternopil’ State Medical University, Ukraine in 2005 (with honours). After receiving his first degree specialization in the field of general surgery (2008) Dr. Forostyak has continued his education at the 2nd Faculty of Medicine at Charles University in Prague and Institute of Experimental Medicine at Czech Academy of Sciences.
He has defended his doctoral thesis in 2012 and received a title PhD in Neuroscience. During his doctoral and postdoctoral years he has received several prestigious fellowships and awards (CORTEX: Marie Curie Early Stage Training Net; FENS Young Investigator Training Program; Czech Neuroscience Society award for best publication published by a Young Neuroscientist; Development of Research Teams for the BIOCEV; EUROCELLNET travel fellowship etc.) and underwent internship in prestigious universities (Cambridge University, UK; Katholieke Universiteit Leuven, Belgium; Neuroscience Institute Cavalieri Ottolenghi, Italy; University of Pittsburgh, USA). Dr. Forostyak’s research lays in the field of regenerative and translational medicine with a main focus on evaluation of regenerative potential of stem cells (mesenchymal stromal cells; embryonic stem cells; induced pluripotent stem cells etc.) and biomaterials, and their application to cure neurotrauma and neurodegenerative disorders. Current scientific record includes 22 publications (WOS) in prestigious international peer-reviewed journals, 3 book chapters and 3 papers are currently in press. Dr. Forostyak has been principal/co-principle investigator in several research projects. He is acting as a scientific evaluator of national and international grant agencies, but also contributes as a reviewer in prestigious scientific journals. He has been actively participating at numerous national and international conferences, but also acted as an organising committee member at several international meetings.
Petr Koška, M.Eng., MBA
Petr Koška is Chief Executive Officer of PrimeCell Therapeutics Inc. and Vice-Chairman of the Board of Directors of the National Cell and Tissue Centre Inc. (one of the subsidiaries of PrimeCell Therapeutics). He joined PrimeCell Therapeutics in January 2013 holding a variety of leadership positions over the course of his career. Mr Koska is a well-known professional within the healthcare industry in the Czech Republic. He is a respected manager, who boasts of many years of experience leading large medical facilities.
Prior to his position in PrimeCell Therapeutics, since 2008 he was Chief Executive Officer at one of the largest university hospitals in the Czech Republic, namely, St. Anne´s University hospital Brno. In his previous position he gained knowledge of transferring medical science and research into clinical practice. Additionally, he was the head of a unique team of professionals who were involved with the development of an international centre of clinical research within the premises of St. Anne´s hospital, namely, International Clinical Research Center (ICRC). This centre was developed in co-operation with Mayo Clinic, Rochester, Minnesota, USA.
He started his professional career in 1996 at the University hospital Brno, where he held various leading positions until 2007, when he was elected General Director. In 1997 – 1998 he was one of the three key figures involved in the most unique plan in the healthcare industry in the Czech Republic up-to-date, which was the merger of university hospitals in the Brno region.
Mr Koška graduated at the Technical University Brno. Later, he obtained the MBA degree at Prague International Business School. Currently he is the candidate for PhD in business (DBA). In 2008 – 2012 he was a member of the scientific committee at the Medical faculty of Masaryk University in Brno.
Mgr. Iveta Schmiedová
Iveta Schmiedová has graduated in 2015 from the Faculty of Science at Masaryk University in Biochemistry.
During her studies, she worked as an intern at the University of Veterinary and Pharmaceutical Sciences in Brno where she participated in research focused on hypoglycemic prevention for her Bachelor thesis and later also Master thesis. The main focus was on the formulation and testing of micro-pharmaceutical products with high glucose content and semipermeable membrane which provided a gradual release of glucose. With this research, she won “Science Slam”, a competition which popularizes current research and development. Afterward she took part in the competition European final in Vienna.
After graduation, she worked as an analyst in company Oncomed Manufacturing, which produces cytostatic injections.
Since 2017 Iveta works at Primecell as the responsible person for amniotics membranes. She cooperated on development of AMNIODERM and is an inventor in patent CZ307603 ZPŮSOB PŘÍPRAVY MATERIÁLU NA BÁZI AMNIOVÉ MEMBRÁNY A MATERIÁL PŘIPRAVITELNÝ TÍMTO ZPŮSOBEM and patent EP3505196 METHOD OF PREPARATION OF AMNIOTIC MEMBRANE-BASED MATERIAL AND A MATERIAL OBTAINABLE BY SAID METHOD.
Václav Jirků, MD
Mgr. Igor Hlásenský
Legal matters of PrimeCell Therapeutics are in hands of a team of in-house lawyers led by Igor Hlásenský, young but well-experienced specialist in medical law as well as commercial and administrative law. Upon finishing his studies at the Faculty of Law of Masaryk University in Brno in 2010 he worked for a respected law firm and later moved up to the Ministry of Health to became a main lawyer, inspector, and deputy head of Inspectorate of narcotic drugs and psychotropic substances.
During his career Igor attended many conferences, trained people in legal consciousness and was a part of the European Commission delegation to Serbia for the purpose of bringing this country’s legislation into line with the European law. Igor is a major author of the text of the Czech Act On Drug Precursors and certain other general binding regulations and contributed significantly to terminate complicated and hyped cases.
Nowadays Igor is ranked among leading experts in legal obligations related to handling with tissues and cells and he strongly helps PrimeCell Therapeutics to conclude all the necessary contracts and conduct its activities in full compliance with the law.
Jiří Matuška, MD
Ivo Kristen, M. Eng.
Elen Šťastná, MD
Dr. Elen Šťastná graduated from Charles University in Hradec Kralové in general medicine. After obtaining a first degree specialization in the field of general medicine she worked in this field until 2000. She has been involved in the projects of preventive medicine and projects aimed at improving the quality of life. She has worked at the Danish pharmaceutical and nutraceutical company Pharma Nord at managerial position in the field of education. Dr. Šťastná also provides consulting and advisory services in marketing communications activities, strategic planning and PR. She is The President of Soroptimist International Prague-world, prestigious women’s organizations with direct access to the UN and other international organizations, such as UNESCO and the Council of Europe. Soroptimist International seeks to improve access to health care, doctors, midwives and applies to the fight against the spread of AIDS and transmission of the disease from mother to newborn and improvement of living conditions of women and children.
Dr. Štastná is the founder of the AA Homolka Club at the Department of Pediatric Allergy and Clinical Immunology Hospital Homolka, whose activities contribute to the improvement of awareness and better care for children with allergy and asthma.
Zdeněk Kořístek, MD
Michal Zahradníček, one of the founders of PrimeCell Therapeutics, is an investor and acts as a key figure in several high-tech companies in the Czech Republic and the Central and Eastern European region. He began his career in 1993, working as an economist for several international companies. Since 2001, he has been involved in investments in areas with high innovation potential. He acted as an advisor of the Ministry of Finance of the Slovak Republic, also taking part in health reform preparations. In 2004, he was awarded the title Manager of the Year for a Medium-Size Company and he was listed among the TOP 10 most successful Czech managers. Michal Zahradníček graduated from the Brno University of Technology. He then continued his studies at the Technical University in Darmstadt in Germany and at the Manchester Metropolitan University in the UK.
Petr Čumba, M.Eng.
Ing. Petr Čumba graduated in the Brno University of Technology and in the course of his career, he held management positions in financial institutions, trading and manufacturing companies. Coming from a group SAB Finance – MPU, where was working as a chief financial officer in 2013-2016, he stood at the preparation of the transformation of MPU to a bank and ensure the implementation of new European legislation for the financial sector to internal processes. During his work for both companies there has been negligible growth in their profitability.
In 2010-2012 he was responsible for the financial management of manufacturing companies BONATRANS GROUP and MANEX Industrial Automation, where he led the crisis management team that has successfully completed the reorganization of the company.
Until 2009, he worked nearly 15 years in companies operating in oil and gas division of the KKCG Group. The longest in the MND, the biggest Czech oil and gas producer, where in addition to membership in the company boards, he managed finances in the parent company and subsidiaries. He was responsible for all standard economic activities, cash flow management in the group, both internal and external financing, management of domestic and foreign subsidiaries, development of gas trading after the end of state regulation, sales of crude oil, implementation of system of central purchasing, several transformations of companies in the group and other related activities.
Ing. Jan Lipenský, Ph.D.
Vystudoval obor Živočišné biotechnologie na Agronomické fakultě Mendelovy univerzity v Brně. Doktorské studium absolvoval na ústavu Morfologie, fyziologie a genetiky zvířat téže fakulty. Po řadu let pracoval ve Výzkumném ústavu živočišné výroby, v.v.i. Mezi jeho zaměření patřila především oblast reprodukce a vývoje nových technologií chovu.
